TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05648266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continous SAPB (Ropivacain)
Description: postoperative SAPB and pain catheter with continous administered (5ml/h Ropivacain 0,2%) for 48h

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: institutional standard of care pain medication protocol
Description: institutional standard of care pain medication protocol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: institutional standard of care pain medication protocol
Description: institutional standard of care pain medication protocol
Study: NCT06360146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilisation
Description: Breathing exercises, inspiratory muscle strength, postural drainage, functional exercise (stand up and sitting down on the chair, walking inward, back-ward ,and sideways), weight shifts from left to right, step up inside the patch , one leg stand, squatting leaning against wall) for three times per the day and repetition fifteen times (3 times per day for 15 repetition) and supervised walking with increments of 2 minutes, as tolerated up to 6 minutes or more at the morning, afternoon, evening and at night.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early mobilisation
Description: Breathing exercises, inspiratory muscle strength, postural drainage, functional exercise (stand up and sitting down on the chair, walking inward, back-ward ,and sideways), weight shifts from left to right, step up inside the patch , one leg stand, squatting leaning against wall) for three times per the day and repetition fifteen times (3 times per day for 15 repetition) and supervised walking with increments of 2 minutes, as tolerated up to 6 minutes or more at the morning, afternoon, evening and at night.
Study: NCT06468956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1819
Description: SHR-1819 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1819
Description: SHR-1819 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT06314334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab+Pegaspargase
Description: 1. Sintilimab, 200mg intravenous drip, on day 1;~2. pegaspargase, 2000U/m\^2, capped at 3750U, intramuscular, day 1;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-GemOx
Description: 1. pegaspargase 2000U/m\^2, capped at 3750U on day 1, intramuscular;~2. gemcitabine 1.0g/m\^2 on day 1 and day 8, intravenous drip;~3. oxaliplatin 130mg/m\^2 on day 1, intravenous drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GELAD
Description: 1. gemcitabine 1.0g/m\^2 on day 1, intravenous drip;~2. etoposide 60mg/m\^2 on day 1-3, intravenous drip;~3. pegaspargase 2000U/m\^2, capped at 3750U on day 1,intramuscular;~4. dexamethasone 20mg on day 1-4, intravenous drip.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity modulated radiotherapy (50-56Gy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity modulated radiotherapy (50-56Gy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity modulated radiotherapy (50-56Gy)
Study: NCT06256172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlink
Description: The 10 Patients enrolled in this arm tested the ue of Medlink in Measuring and reporting their Physiological Paramters in Oder to remotely obtain access to health care for the following diseases: Myasthenia Gravis, Hypertension, Chronic Heart Failure, Diabetes Mellitus, and Chronic Obstruction Pulmonary Disorder.
Study: NCT05305352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate dietary intervention
Description: The experimental group will be counseled about very low carbohydrate diet i.e., \<10% carbohydrate,40-50% protein and lipid in diet).
Study: NCT05973734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of recipient T regulatory cell
Description: Patients will undergo a single apheresis collection with a target total blood volume of 20-30 L and the collected cells used as the source of purified Tregs to be infused following the islet transplantation. In the event a patient is unable to meet the collection target, a second collection may be performed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of concomitant Donor Derived Vertebral Bone Marrow
Description: The cells from the donor VB and spleen are processed under cGMP conditions and released for infusion after the respective recipient has undergone transplant and conditioning. Under this protocol, the donor's VB will be obtained at the same time as the pancreatic islets and will be the source of HSC for infusion with the intent to establish immune tolerance to the donor's pancreatic islet cells. Subjects will receive one infusion of allogeneic cadaveric islets. Subjects will receive induction therapy with ATG and Belatacept and maintenance immunosuppression with Tacrolimus Extended-release tablets (Envarsus XR) and Mycophenolate Mofetil (MMF). After islet transplantation, the VBM cells will be infused in one time window: on day 0-1. Subjects will undergo closed-loop insulin pump glucose control peri-transplant.
Study: NCT05695807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carboxytherapy
Description: Device generating CO2 gas

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carboxytherapy
Description: Device generating CO2 gas

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carboxytherapy
Description: Device generating CO2 gas
Study: NCT06368102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin
Description: Total 2g vs 3g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin
Description: Total 2g vs 3g
Study: NCT05860088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beef Diet
Description: Controlled-Feeding Diet Intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetarian Diet
Description: Controlled-Feeding Diet Intervention
Study: NCT05821699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LCS (Life Care Specialist)
Description: The LCS will work with the patient to create a pain management plan focused on behavioral education. The LCS interventions can encompass all, but not limited to, the information included below:~* Opioid Risk Education~* Therapeutic Intervention~* Clinical Pain Coordination
Study: NCT05698368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindset intervention
Description: Participants receive a digital mindset intervention to improve mindsets about osteoarthritis and exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Participants receive a series of osteoarthritis education videos and reflective questions that matches the digital mindset intervention in duration and attention.
Study: NCT05481307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2202
Description: Take it once a day per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2203
Description: Take it once a day per period
Study: NCT05865197

Intervention type: OTHER
Intervention: Data collection
Description: Data collection of clinically relevant signals using home-based sensor system
Study: NCT05463861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lemborexant
Description: Lemborexant tablet administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match Lemborexant tablet administered orally once daily.
Study: NCT06090656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab combined with Sintilimab
Description: Bevacizumab combined with sintilimab, sindilizumab 200 mg IV d1, Q3W, combined with bevacizumab 15 mg/kg IV d1, Q3W treatment, treatment continued until disease progression, development of intolerable toxic reactions

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcatheter arterial chemoembolization
Description: Transcatheter arterial chemoembolization, patients were treated with cTACE, and the efficacy was assessed by repeat CT/MRI 1 month after the initial treatment, and if the tumor still had arterial phase enhancement, TACE treatment could be supplemented until treatment failure and withdrawal of consent.
Study: NCT05743920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help Forest Bathing
Description: The self-help forest bathing includes two sessions (i.e., participants will perform the first intervention within week 1 to 3, and the second intervention within week 4 to 6) that are related to the following forest bathing activities : (a) forest meditation, (b) forest walking, (c) calling attention to sensory experiences of the forest, including seeing, hearing, touching, and smelling, and (d) building connection to the nature by partnership invitation. Each session will last for 45 minutes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-help Forest Bathing
Description: The self-help forest bathing includes two sessions (i.e., participants will perform the first intervention within week 1 to 3, and the second intervention within week 4 to 6) that are related to the following forest bathing activities : (a) forest meditation, (b) forest walking, (c) calling attention to sensory experiences of the forest, including seeing, hearing, touching, and smelling, and (d) building connection to the nature by partnership invitation. Each session will last for 45 minutes.
Study: NCT06132035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG-P5 peptide
Description: Patient will instill daily 1 package of CG-P5 peptide eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will instill daily 1 package of Placebo eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection [Eylea]
Description: Patient will receiver Eylea® (Aflibercept) intravitreal injection once in a month
Study: NCT05551533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kampung Care App
Description: Please refer to the previous session
Study: NCT05416190

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lupus anticoagulant testing
Description: The patient will have a visit during which a blood sample will be taken, a clinical examination will be performed, and data will be collected.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lupus anticoagulant testing
Description: The patient will have a visit during which a blood sample will be taken, a clinical examination will be performed, and data will be collected.
Study: NCT05821699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LCS (Life Care Specialist)
Description: The LCS will work with the patient to create a pain management plan focused on behavioral education. The LCS interventions can encompass all, but not limited to, the information included below:~* Opioid Risk Education~* Therapeutic Intervention~* Clinical Pain Coordination

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients will receive the current standard-of-care for pain management in the aftermath of surgery: a standardized prescription protocol, hospital-system approved discharge instructions which provide written instruction on how to taper opioid use, links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
Study: NCT05361616

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PBM Ortho
Description: The device will be used by the patients at home for one 8 minutes per day (4 minutes each upper and lower) for 7 days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PBM Ortho
Description: The device will be used by the patients at home for one 8 minutes per day (4 minutes each upper and lower) for 7 days.
Study: NCT04678583

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection of colorectal liver metastases
Description: Comparison of two liver surgery methods

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection of colorectal liver metastases
Description: Comparison of two liver surgery methods
Study: NCT06181526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aleeto
Description: According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection, and the specific dosage and administration method of Aleeto will depend on the grouping.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aleeto
Description: According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection, and the specific dosage and administration method of Aleeto will depend on the grouping.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aleeto
Description: According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection, and the specific dosage and administration method of Aleeto will depend on the grouping.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aleeto
Description: According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection, and the specific dosage and administration method of Aleeto will depend on the grouping.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravenous injection
Description: According to the groups, patients would be treated with Aleeto or placebo +100ml sodium chloride injection via intravenous injection, depend on the grouping

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravenous injection
Description: According to the groups, patients would be treated with Aleeto or placebo +100ml sodium chloride injection via intravenous injection, depend on the grouping

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravenous injection
Description: According to the groups, patients would be treated with Aleeto or placebo +100ml sodium chloride injection via intravenous injection, depend on the grouping

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravenous injection
Description: According to the groups, patients would be treated with Aleeto or placebo +100ml sodium chloride injection via intravenous injection, depend on the grouping

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intrathecal injection
Description: According to the groups, patients would be treated with Aleeto or placebo + 8ml sodium chloride injection via intrathecal injection, depend on the grouping.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intrathecal injection
Description: According to the groups, patients would be treated with Aleeto or placebo + 8ml sodium chloride injection via intrathecal injection, depend on the grouping.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intrathecal injection
Description: According to the groups, patients would be treated with Aleeto or placebo + 8ml sodium chloride injection via intrathecal injection, depend on the grouping.
Study: NCT05377853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Kinesthetic Navigational Training
Description: Training with tactile maps to improve spatial memory capability for enhanced navigational capabilities.
Study: NCT05298488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home office
Description: Working from home

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home office
Description: Working from home

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Office
Description: Working at the office

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Office
Description: Working at the office
Study: NCT05219357

Intervention type: OTHER
Group type: OTHER
Intervention: Ayu-Care
Description: Ayurveda treatment modalities includes three parts to manage mental health Satwawajay Chikitsa, Yuktivyapashray and Daivyapashray Chikitsa. It is based on personalised whole person approach.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual-Care
Description: Management strategies includes restraints, emergency medications, behavioral interventions, with a special focus on the pharmacological interventions.
Study: NCT05625984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fascigel
Description: The product is a Class III Medical Device. Structure is made by 1% sodium hyaluronate polysaccharide in normal saline solution.
Study: NCT04931264

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: YuWell YE660D Electronic Sphygmomanometer
Description: Measurement blood pressure by YuWell YE660D Electronic Sphygmomanometer and Desk Mercury Sphygmomanometer
Study: NCT06012682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.~The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.~The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin
Study: NCT05243875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation
Description: COVID education for people with lupus plus tailored guidance in ordering COVID tests and making testing and vaccination appointments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: COVID education for people with lupus.
Study: NCT05073666

Intervention type: OTHER
Intervention: NO INTERVENTION
Description: NO INTERVENTION
Study: NCT03947190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M
Description: R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M
Description: R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63/MVA ME-TRAP
Description: ChAd63, chimpanzee adenovirus serotype 63; ME-TRAP, multiple epitope string fused to the thrombospondin-related adhesion protein; MVA, modified vaccinia Ankara.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge
Description: PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge
Description: PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge
Description: PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.
Study: NCT05306626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Emotion Awareness and Mental Health (BEAM)
Description: The BEAM Program is based on best-practices in telehealth and science-based program design principles aimed at promoting maternal mental health and supportive parenting. The BEAM Program mobile application is designed and managed by Tactica Interactive and hosted on the University of Manitoba secure servers. The weekly group telehealth sessions will be led by clinical coaches (a mental health professional or trainee) and will use the secure videoconferencing platform Zoom (Healthcare license). Parent coaches will be mothers who have recently participated in another research group-based mental health intervention. Parent coaches will engage with participants on the community peer support forum and attend weekly telehealth sessions. The therapeutic aims of the BEAM program are to improve anxiety and depression symptoms and parenting skills using content that draws from the Unified Protocol, and emphasizes self-compassion, effective communication practices, and social support networks.
Study: NCT04894721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: 0,6mg/kg of weight orally on days 1 and 7

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance with similar physical characteristics as ivermectin, without the active drug ingredient
Study: NCT05208502

Intervention type: DEVICE
Intervention: DSA monitor
Description: Next Generation SedLine features an enhanced signal processing engine, which provides processed EEG parameters. This four channel EEG monitor for the monitoring of perioperative anesthesia depth prevent overdose of medication and may help for individualized anesthetic plan
Study: NCT05797012

Intervention type: OTHER
Group type: OTHER
Intervention: To assess headache severity, head posture, cervical muscle endurance and neck disorders.
Description: To assess headache severity, head posture, cervical muscle endurance and neck disorders.
Study: NCT05823402

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SPECT/CT
Description: SPECT/CT imaging can generate 3-dimensional images of the location where the PSMA radioligand therapy has accumulated in the body. SPECT/CT imaging can also measure doses of radiation delivered to those locations.
Study: NCT05135871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Single fasted oral dose of Mavacamten 15/25 mg on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Single fasted oral dose of Mavacamten 15/25 mg on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Single fasted oral dose of Mavacamten 15/25 mg on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavacamten
Description: Single fasted oral dose of Mavacamten 15/25 mg on Day 1